ArchPoint Investors’s AbCellera Biologics ABCL Stock Holding History

ArchPoint Investors’s Portfolio ABCL Stock Details ABCL Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q3	–	Sell	-115,055	Closed	-$903K	–	79
2026 Q2	$903K	Hold	115,055	–	–	0.19%	55
2026 Q1	$402K	Hold	115,055	–	–	0.1%	61
2025 Q4	$393K	Hold	115,055	–	–	0.09%	67
2025 Q3	$579K	Hold	115,055	–	–	0.16%	53
2025 Q2	$395K	Hold	115,055	–	–	0.12%	58
2025 Q1	$257K	Hold	115,055	–	–	0.08%	62
2024 Q4	$337K	Hold	115,055	–	–	0.11%	57
2024 Q3	$299K	Hold	115,055	–	–	0.1%	61
2024 Q2	$341K	Hold	115,055	–	–	0.13%	60
2024 Q1	$521K	Hold	115,055	–	–	0.22%	52
2023 Q4	$657K	Hold	115,055	–	–	0.27%	35
2023 Q3	$529K	Hold	115,055	–	–	0.2%	42
2023 Q2	$743K	Hold	115,055	–	–	0.29%	39
2023 Q1	$868K	Hold	115,055	–	–	0.38%	34
2022 Q4	$1.17M	Sell	115,055 -502,158	-81%	-$5.8M	0.55%	33
2022 Q3	$6.1M	Sell	617,213 -13,113	-2%	-$144K	2.49%	12
2022 Q2	$6.71M	Buy	630,326 +169,037	+37%	+$1.43M	2.66%	11
2022 Q1	$4.5M	Hold	461,289	–	–	1.55%	18
2021 Q4	$6.6M	Hold	461,289	–	–	1.96%	15
2021 Q3	$9.24M	Buy	+461,289	New	+$8.15M	2.77%	7

Other funds holding ABCL

Capital World Investors Los Angeles, California $824B AUM 37.44% 1-Year Est. Return

TD Waterhouse Canada Toronto, Ontario, Canada $38.4B AUM 30.28% 1-Year Est. Return

Jane Street New York $1.19T AUM 51.51% 1-Year Est. Return

Franklin Resources San Mateo, California $474B AUM 32.39% 1-Year Est. Return

American Century Companies Kansas City, Missouri $229B AUM 33.35% 1-Year Est. Return

DnB Asset Management Oslo, Norway $38B AUM 25.01% 1-Year Est. Return

Guardian Partners Toronto, Canada $1.13B AUM 28.37% 1-Year Est. Return

State Street Boston, Massachusetts $3.44T AUM 36.12% 1-Year Est. Return

Renaissance Technologies New York $73.4B AUM 32.8% 1-Year Est. Return

Osaic Holdings Scottsdale, Arizona $83.6B AUM 19.78% 1-Year Est. Return

ArchPoint Investors's ABCL Position: Q3 2026 in Review

ArchPoint Investors sold out of AbCellera Biologics (ABCL) in Q3 2026, closing a stake of 115,055 shares — an estimated $903K sold.

ArchPoint Investors first reported a position in ABCL in Q3 2021 and held it in 20 quarters. The position peaked at $9.24M in Q3 2021. 89 funds tracked by Wall St. Rank hold ABCL as of Q3 2026.

ArchPoint Investors reported no remaining AbCellera Biologics position as of Q3 2026 after selling out during the quarter.
ArchPoint Investors sold 115,055 AbCellera Biologics shares in Q3 2026, an estimated $903K.
ArchPoint Investors first reported a position in AbCellera Biologics in Q3 2021 and held it in 20 quarters.
ArchPoint Investors's AbCellera Biologics position peaked at $9.24M in Q3 2021.
89 funds tracked by Wall St. Rank held AbCellera Biologics as of Q3 2026.

Based on ArchPoint Investors's 13F filing for Q3 2026, filed 13 Nov 2026.